Latest Content

How social media algorithms push violent clips, fueling desensitization, irritability, and compulsive scrolling—plus practical screening and treatment tips for clinicians.

Reality TV shows therapy and diagnoses as entertainment—raising stigma, misinformation, and suicide concerns. Get guidance for clinician-patient talks.

This Presidents Day, H. Steven Moffic, MD, links ICE raids to trauma and fear, urges ethical action and creative protest to protect immigrants and public mental health.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Explore how seizure control, antiepileptics, and surgery can trigger psychosis in epilepsy, and what guides diagnosis and treatment.

New study links acne to higher eating-disorder risk, urging dermatologists and psychiatrists to spot warning signs and coordinate care.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

Learn how psychiatrists lead through change with emotional intelligence, mentorship, and early leadership roles that boost teamwork and patient safety.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

A psychiatrist fights denials for GLP‑1 weight-loss drugs, exposing how high costs and rigid rules deepen obesity care inequities.